☆ 4.7 Article

Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer

JOURNAL OF CLINICAL MEDICINE (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial

Gunn Huh et al.

Summary: In patients with advanced pancreatic ductal adenocarcinoma after FOLFIRINOX failure, GnP demonstrated favorable efficacy with acceptable toxicity.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Pancreatic cancer

Jonathan D Mizrahi et al.

LANCET (2020)

Add to Collection

Article Oncology

Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis

Heejung Chae et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure

Naoki Mita et al.

JOURNAL OF CLINICAL MEDICINE (2019)

Add to Collection

Article Oncology

A phase II study of modified FOLFIRINOX for chemotherapy-na < ve patients with metastatic pancreatic cancer

Masato Ozaka et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)

Add to Collection

Article Oncology

The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer

Kyoko Yamaguchi et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)

Add to Collection

Article Oncology

A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer

Kensaku Yoshida et al.

ONCOTARGET (2017)

Add to Collection

Article Oncology

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

Alix Portal et al.

BRITISH JOURNAL OF CANCER (2015)

Add to Collection

Article Oncology

Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity

Yue Zhang et al.

EXPERIMENTAL HEMATOLGY & ONCOLOGY (2015)

Add to Collection

Article Oncology

Phase II study of FOLFIRINOX for chemotherapy-naive Japanese patients with metastatic pancreatic cancer

Takuji Okusaka et al.

CANCER SCIENCE (2014)

Add to Collection

Review Oncology

Chemotherapy-Induced Peripheral Neurotoxicity: A Critical Analysis

Susanna B. Park et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2013)

Add to Collection

Article Medicine, General & Internal

Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy A Randomized Clinical Trial

Ellen M. Lavoie Smith et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)

Add to Collection

Article Medicine, General & Internal

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Medicine, General & Internal

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

Add to Collection

Article Oncology

Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02

Kojiro Shimozuma et al.

SUPPORTIVE CARE IN CANCER (2009)

Add to Collection

Article Oncology

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

A de Gramont et al.

JOURNAL OF CLINICAL ONCOLOGY (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.